Four-star-rated analyst Daniel Grosslight at Citi reiterated his Sell rating on Hims & Hers Health (HIMS) stock yesterday, ...

Takeda Pharmaceutical has a robust drug discovery pipeline to meet future clinical demand. Check out the upside and downside ...

If you have any oyster crackers in your pantry, be sure to check their sell-by date and UPC code to ensure they aren't among this recalled batch.

CervoMed has announced positive results from the extension phase 2b RewinD-LB study of neflamapimod for dementia with Lewy ...

The latest HPRA inspection in February 2025 was highly successful-both QC licences were renewed, and viral vector manufacturing was added to the MIA (IMP) licence. This means the Shannon site can ...

In a regulatory filing, DexCom (DXCM) disclosed that on March 4, the company received a warning letter from the U.S. FDA following inspections ...

Duterte accused of crimes against humanity for an estimated 30,000 deaths during tenure as mayor, Philippines president.

AL002 misses Phase 2 goal in early Alzheimer's. Key Phase 3 data for latozinemab in 2025. Click here to read why ALEC is a ...

Often when Trump picks fights abroad he seems to give a significant political boost to his antagonists. We’re living through ...

Sri Lanka will expand the current administered prices to 862 drugs in the market, Health Minister Nalinda Jayatissa said ...

Arvinas stock lost half its value Tuesday after the biotech company reported mixed results from its Pfizer-partnered breast ...

You could do a hell of a lot worse than having Brian Tyree Henry and Wagner Moura—both very compelling screen presences in ...